Barclays PLC Has $1.51 Million Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)

Barclays PLC increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 193,068 shares of the technology company’s stock after acquiring an additional 17,384 shares during the quarter. Barclays PLC owned about 0.17% of Cogent Biosciences worth $1,506,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Cogent Biosciences during the 4th quarter valued at $88,000. E Fund Management Co. Ltd. purchased a new position in shares of Cogent Biosciences in the 4th quarter worth approximately $89,000. Proficio Capital Partners LLC purchased a new stake in shares of Cogent Biosciences during the 4th quarter valued at $93,000. Teacher Retirement System of Texas raised its position in Cogent Biosciences by 15.4% in the fourth quarter. Teacher Retirement System of Texas now owns 17,983 shares of the technology company’s stock worth $140,000 after acquiring an additional 2,396 shares during the period. Finally, Virtu Financial LLC purchased a new position in Cogent Biosciences in the third quarter valued at approximately $147,000.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Robert W. Baird reduced their target price on Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. Piper Sandler raised shares of Cogent Biosciences to a “strong-buy” rating in a report on Friday, March 7th. Scotiabank assumed coverage on Cogent Biosciences in a research note on Friday, March 7th. They set a “sector outperform” rating and a $17.00 price objective for the company. Finally, Wedbush reaffirmed a “neutral” rating and set a $11.00 price target on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.43.

Cogent Biosciences Trading Up 4.3 %

Cogent Biosciences stock opened at $5.87 on Friday. The company has a market capitalization of $668.33 million, a price-to-earnings ratio of -2.37 and a beta of 1.91. Cogent Biosciences, Inc. has a 12 month low of $3.72 and a 12 month high of $12.61. The business’s fifty day simple moving average is $5.86 and its two-hundred day simple moving average is $7.98.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.